- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06208878
A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies
May 1, 2024 updated by: CRISPR Therapeutics AG
A Long-term Follow-up Study of Subjects With Malignancies Treated With CRISPR CAR T Cellular Therapies
This study will evaluate the long-term safety and efficacy of CRISPR CAR T cellular therapies
Study Overview
Status
Enrolling by invitation
Conditions
Intervention / Treatment
Detailed Description
All subjects with hematological and solid malignancies who are enrolled in a parent study and were exposed to allogeneic CRISPR CAR T cellular therapy will be asked to participate in this long-term follow-up (LTFU) study.
Subjects who have completed the parent study for the protocol-defined duration, or who have discontinued the parent study early, or who are in secondary follow-up (follow up of subjects with progressive disease or who receive a subsequent line of anticancer therapy) in the parent study may enroll in this LTFU study.
This will allow for collection of long-term efficacy data (as applicable) and safety data up to 15 years post-treatment with CRISPR CAR T cellular therapies.
Study Type
Observational
Enrollment (Estimated)
70
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Yale New Haven Hospital
-
-
Kansas
-
Westwood, Kansas, United States, 66205
- University of Kansas
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University Saint Louis
-
-
New York
-
Bronx, New York, United States, 10467
- Montefiore Medical Center
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health and Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center
-
San Antonio, Texas, United States, 78229
- Methodist Hospital-Sarah Cannon
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
All subjects with hematological and solid malignancies who are enrolled in a parent study and were exposed to allogeneic CRISPR CAR T cellular therapy will be asked to participate in this long-term follow-up (LTFU) study.
Subjects who have completed the parent study for the protocol-defined duration, or who have discontinued the parent study early, or who are in secondary follow-up (follow up of subjects with progressive disease or who receive a subsequent line of anticancer therapy) in the parent study may enroll in this LTFU study.
This will allow for collection of long-term efficacy data (as applicable) and safety data up to 15 years post-treatment with CRISPR CAR T cellular therapies.
Description
Inclusion Criteria:
- Able to understand and comply with protocol-required study procedures and voluntarily sign and date a written informed consent document.
- Must have received CRISPR CAR T cellular therapy.
Exclusion Criteria:
- There are no specific exclusion criteria.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Non Interventional
All subjects with hematological and solid malignancies who are enrolled in a parent study and were exposed to allogeneic CRISPR CAR T cellular therapy will be asked to participate in this long-term follow-up (LTFU) study.
|
Safety and Efficacy Assessment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The incidence of adverse events, serious adverse events and adverse events of special interest related to CRISPR CAR T cellular therapy treatment.
Time Frame: 15 years
|
The number and percentage of subjects with CRISPR CAR T cellular therapy related SAEs and AESIs will be summarized.
|
15 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The overall survival and duration of remission/response following CRISPR CAR T cellular therapy treatment
Time Frame: 15 years
|
Overall survival will be calculated as the time between the initial dose of CRISPR CAR T cellular therapy in the parent study and death due to any cause.
Duration of remission/response will be calculated as the time between the first objective response to first disease progression or death due to any cause.
|
15 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 22, 2023
Primary Completion (Estimated)
August 1, 2038
Study Completion (Estimated)
August 1, 2038
Study Registration Dates
First Submitted
December 12, 2023
First Submitted That Met QC Criteria
January 5, 2024
First Posted (Actual)
January 17, 2024
Study Record Updates
Last Update Posted (Actual)
May 2, 2024
Last Update Submitted That Met QC Criteria
May 1, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CRSP-ONC-LTF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematologic Malignancy
-
St. Jude Children's Research HospitalRecruitingRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyUnited States
-
Epizyme, Inc.WithdrawnRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyUnited States
-
Scripps Translational Science InstituteCompleted
-
Millennium Pharmaceuticals, Inc.Completed
-
Guardant Health, Inc.CompletedNon-Hematologic MalignancyUnited States
-
CCTU- Cancer ThemeRecruitingCancer | Non-Hematologic MalignancyUnited Kingdom
-
Century Therapeutics, Inc.RecruitingHematological Malignancy | Solid Tumor MalignancyUnited States
-
Princess Maxima Center for Pediatric OncologyRecruitingRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyNetherlands
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingHematologic MalignancyChina
-
Innovent Biologics (Suzhou) Co. Ltd.Recruiting
Clinical Trials on Non Interventional
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI)RecruitingUse of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMCHIV Infections | Cancer | HPV-Related Malignancy | Anal Cancer | HIV-Associated Malignant Neoplasm | AIDS Related Lymphoma | AIDS-related Kaposi Sarcoma | AIDS-Related MalignancyUnited States
-
Universitätsklinikum Hamburg-EppendorfSandozUnknownPsoriasisDenmark, Spain, Germany, Poland
-
Bristol-Myers SquibbWithdrawnNon-valvular Atrial FibrillationUnited States
-
Papworth Hospital NHS Foundation TrustInnovate UK; Cystic Fibrosis Trust; US Cystic Fibrosis FoundationRecruitingCystic FibrosisUnited Kingdom
-
Royal Marsden NHS Foundation TrustRecruiting
-
Regeneron PharmaceuticalsRecruitingHemophilia BUnited States, Germany, United Kingdom, Canada
-
Henri Mondor University HospitalEuropean Society of Intensive Care MedicineRecruitingFournier Gangrene | Necrotizing Soft Tissue Infection | Necrotizing FasciitisFrance
-
Medtronic Cardiac Rhythm and Heart FailureCompleted
-
Respiratory Effectiveness GroupBoehringer IngelheimCompletedChronic Obstructive Pulmonary DiseaseKorea, Republic of, Singapore, Malta, Italy, Slovenia, Spain
-
Eurasian Association of TherapistsCompletedCardiovascular Diseases | Pneumonia | Hypertension | Diabetes | Covid19 | Coronary Heart Disease | Copd | CKD | Overweight and Obesity | SARS-CoV-2 Infection | Cardiac EventRussian Federation